Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | TPMT | P51580 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | HPGD | P15428 | 6/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30810326 | 0.84 | KDM4E (0.44) | HSD17B10KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL4878432 | 0.84 | KDM4E (0.44) | HSD17B10KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL10370336 | 0.83 | TPMT (0.51) | HSD17B10TPMTKDM4EALDH1A1HPGD | |
| SCHEMBL7828568 | 0.81 | PKM (0.49) | HSD17B10TPMTKDM4EALDH1A1HPGD | |
| SCHEMBL10920134 | 0.81 | KDM4E (0.55) | HSD17B10TPMTKDM4EALDH1A1HPGD | |
| SCHEMBL4745038 | 0.81 | KDM4E (0.37) | HSD17B10TPMTKDM4EALDH1A1MAPT | |
| SCHEMBL19348178 | 0.80 | KDM4E (0.45) | HSD17B10KDM4EALDH1A1MAPTPKM | |
| SCHEMBL19100974 | 0.79 | HSD17B10 (0.49) | HSD17B10KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL9191019 | 0.79 | KDM4E (0.53) | HSD17B10TPMTKDM4EALDH1A1HPGD | |
| SCHEMBL27801015 | 0.79 | TPMT (0.49) | HSD17B10TPMTKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240100031-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIONS CONTAINING PIPERLONGUMINE-BASED COMPOUND AS ACTIVE INGREDIENT | HUSCION CO., LTD. (KR) | 2024-03-28 | — | — | US | disclosed |
| US-11878971-B2 | Piperlongumine-based compound and immuno regulator comprising the same | HUSCION CO., LTD. (KR) | 2024-01-23 | — | — | US | disclosed |
| WO-2023055020-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VASCULAR DISEASES, COMPRISING PIPERLONGUMINE-BASED COMPOUND AS ACTIVE INGREDIENT | 주성수 | 2023-04-06 | — | — | WO | disclosed |
| US-20220213080-A1 | PIPERLONGUMINE-BASED COMPOUND AND IMMUNO REGULATOR COMPRISING THE SAME | HUSCION CO., LTD. (KR) | 2022-07-07 | — | — | US | disclosed |
| WO-2022145923-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIONS CONTAINING PIPERLONGUMINE-BASED COMPOUND AS ACTIVE INGREDIENT | 주식회사 휴사이온 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022145707-A1 | PIPERLONGUMINE-BASED COMPOUND AND IMMUNOMODULATOR COMPRSING SAME | 주식회사 휴사이온 | 2022-07-07 | — | — | WO | disclosed |
| EP-4023301-A2 | PIPERLONGUMINE-BASED COMPOUND AND IMMUNO REGULATOR COMPRISING THE SAME | Huscion Co., Ltd. (KR) | 2022-07-06 | — | — | EP | disclosed |
| US-20170267667-A1 | ALKENYLDIARYLMETHANES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR ANTI-HIV-1 CHEMOTHERAPY | PURDUE RESEARCH FOUNDATION (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267667-A1 | ALKENYLDIARYLMETHANES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR ANTI-HIV-1 CHEMOTHERAPY | PURDUE RESEARCH FOUNDATION (US) | 2017-09-21 | — | — | US | disclosed |
| EP-2325651-B1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INST (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-1587821-B1 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | SCRIPPS RESEARCH INST (US) | 2008-08-20 | — | — | EP | disclosed |
| EP-1587821-A4 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | SCRIPPS RESEARCH INST (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7214695-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214696-B2 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE | 2007-04-05 | — | — | US | disclosed |
| WO-2007005531-A2 | ALKENYLDIARYLMETHANES, FUSED ANALOGS AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | SCRIPPS RESEARCH INSTITUTE, THE | 2006-03-16 | — | — | US | disclosed |
| EP-1587821-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | The Scripps Research Institute (US) | 2005-10-26 | — | — | EP | disclosed |
| US-20040152140-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | THE SCRIPPS RESEARCH INSTITUTE | 2004-08-05 | — | — | US | disclosed |
| WO-2004056315-A2 | COMPOSITIONS AND METHODS FOR STABILIZING TRANSTHYRETIN AND INHIBITING TRANSTHYRETIN MISFOLDING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078186-A1 | Methods for treating transthyretin amyloid diseases | TTR, TTPA, PRNP | HSD17B10 1358/4885TPMT 65/4885KDM4E 4518/4885 |
| US-20240100031-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIONS CONTAINING PIPERLONGUMINE-BASED COMPOUND AS ACTIVE INGREDIENT | SARS1, ACE2, CUL2 | HSD17B10 3435/4885TPMT 93/4885KDM4E 1825/4885 |
| US-11878971-B2 | Piperlongumine-based compound and immuno regulator comprising the same | NFATC1, IRF2BP2, IKBKG | HSD17B10 3850/4885TPMT 1960/4885KDM4E 720/4885 |
| US-20220213080-A1 | PIPERLONGUMINE-BASED COMPOUND AND IMMUNO REGULATOR COMPRISING THE SAME | NFATC1, IRF2BP2, IKBKG | HSD17B10 3850/4885TPMT 1960/4885KDM4E 720/4885 |
| US-20060057644-A1 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding | TTR, TTPA, PRNP | HSD17B10 1691/4885TPMT 105/4885KDM4E 4544/4885 |
| US-20170267667-A1 | ALKENYLDIARYLMETHANES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR ANTI-HIV-1 CHEMOTHERAPY | TYMP, SAMHD1, TYMS | HSD17B10 401/4885TPMT 33/4885KDM4E 1501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.